Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia

Vaccine

Volumn 29, Issue 40, 2011, Pages 6941-6947

  Hickey, Anthony J ^a   Hazlett, Karsten R O ^a   Kirimanjeswara, Girish S ^a,b   Metzger, Dennis W ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Intradermal; Intranasal; Pulmonary; Subunit vaccine; Tularemia

Indexed keywords

ALUMINUM HYDROXIDE; ANTIGEN; ANTISERUM; INTERLEUKIN 12; OUTER MEMBRANE PROTEIN A; PROTEIN ANTIBODY; TULAREMIA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL COUNT; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG EFFICACY; ESCHERICHIA COLI; FRANCISELLA TULARENSIS; HUMORAL IMMUNITY; IMMUNIZATION; LIVER; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SPLEEN; TULAREMIA;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; ESCHERICHIA COLI; FRANCISELLA TULARENSIS; IMMUNE SERA; IMMUNITY, HUMORAL; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECOMBINANT PROTEINS; TULAREMIA;

EID: 80052329242     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.075     Document Type: Article

References (32)

1. Oyston P.C., Sjostedt A., Titball R.W. Tularaemia: bioterrorism defense renews interest in Francisella tularensis. Nat Rev Microbiol 2004, 2:967-978.
2. Ellis J., Oyston P.C., Green M., Titball R.W. Tularemia. Clin Microbiol Rev 2002, 15:631-646.
3. Pechous R.D., McCarthy T.R., Zahrt T.C. Working toward the future: insights into Francisella tularensis pathogenesis and vaccine development. Microbiol Mol Biol Rev 2009, 73:684-711.
4. Salinas L.J., Greenfield R.A., Little S.E., Voskuhl G.W. Tickborne infections in the southern United States. Am J Med Sci 2010, 340:194-201.
5. Larsson P., Oyston P.C., Chain P., Chu M.C., Duffield M., Fuxelius H.H., et al. The complete genome sequence of Francisella tularensis, the causative agent of tularemia. Nat Genet 2005, 37:153-159.
6. Elkins K.L., Cowley S.C., Bosio C.M. Innate and adaptive immunity to Francisella. Ann N Y Acad Sci 2007, 1105:284-324.
7. Isherwood K.E., Titball R.W., Davies D.H., Felgner P.L., Morrow W.J. Vaccination strategies for Francisella tularensis. Adv Drug Deliv Rev 2005, 57:1403-1414.
8. Bakshi C.S., Malik M., Mahawar M., Kirimanjeswara G.S., Hazlett K.R., Palmer L.E., et al. An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine 2008, 26:5276-5288.
9. Bakshi C.S., Malik M., Regan K., Melendez J.A., Metzger D.W., Pavlov V.M., et al. Superoxide dismutase B gene (sodB)-deficient mutants of Francisella tularensis demonstrate hypersensitivity to oxidative stress and attenuated virulence. J Bacteriol 2006, 188:6443-6448.
10. Jia Q., Lee B.Y., Bowen R., Dillon B.J., Som S.M., Horwitz M.A. A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge. Infect Immun 2010, 78:4341-4355.
11. Huntley J.F., Conley P.G., Hagman K.E., Norgard M.V. Characterization of Francisella tularensis outer membrane proteins. J Bacteriol 2007, 189:561-574.
12. Nano F.E. Identification of a heat-modifiable protein of Francisella tularensis and molecular cloning of the encoding gene. Microb Pathog 1988, 5:109-119.
13. Fulop M., Manchee R., Titball R. Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia. Vaccine 1995, 13:1220-1225.
14. Fulop M., Manchee R., Titball R. Role of two outer membrane antigens in the induction of protective immunity against Francisella tularensis strains of different virulence. FEMS Immunol Med Microbiol 1996, 13:245-247.
15. Bevanger L., Maeland J.A., Naess A.I. Competitive enzyme immunoassay for antibodies to a 43,000-molecular-weight Francisella tularensis outer membrane protein for the diagnosis of tularemia. J Clin Microbiol 1989, 27:922-926.
16. Savitt A.G., Mena-Taboada P., Monsalve G., Benach J.L. Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy. Clin Vaccine Immunol 2009, 16:414-422.
17. Su J., Yang J., Zhao D., Kawula T.H., Banas J.A., Zhang J.R. Genome-wide identification of Francisella tularensis virulence determinants. Infect Immun 2007, 75:3089-3101.
18. Hazlett K.R., Caldon S.D., McArthur D.G., Cirillo K.A., Kirimanjeswara G.S., Magguilli M.L., et al. Adaptation of Francisella tularensis to the mammalian environment is governed by cues which can be mimicked in vitro. Infect Immun 2008, 76:4479-4488.
19. Prilipov A., Phale P.S., Van Gelder P., Rosenbusch J.P., Koebnik R. Coupling site-directed mutagenesis with high-level expression: large scale production of mutant porins from E. coli. FEMS Microbiol Lett 1998, 163:65-72.
20. Dekker N., Merck K., Tommassen J., Verheij H.M. In vitro folding of Escherichia coli outer-membrane phospholipase A. Eur J Biochem 1995, 232:214-219.
21. Heller K.B. Apparent molecular weights of a heat-modifiable protein from the outer membrane of Escherichia coli in gels with different acrylamide concentrations. J Bacteriol 1978, 134:1181-1183.
22. Arulanandam B.P., O'Toole M., Metzger D.W. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis 1999, 180:940-949.
23. Baron S.D., Singh R., Metzger D.W. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion. Infect Immun 2007, 75:2152-2162.
24. Duckett N.S., Olmos S., Durrant D.M., Metzger D.W. Intranasal interleukin-12 treatment for protection against respiratory infection with the Francisella tularensis live vaccine strain. Infect Immun 2005, 73:2306-2311.
25. Lynch J.M., Briles D.E., Metzger D.W. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect Immun 2003, 71:4780-4788.
26. Fortier A.H., Slayter M.V., Ziemba R., Meltzer M.S., Nacy C.A. Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect Immun 1991, 59:2922-2928.
27. Kirimanjeswara G.S., Golden J.M., Bakshi C.S., Metzger D.W. Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J Immunol 2007, 179:532-539.
28. Foshay L. A comparative study of the treatment of tularemia with immune serum, hyperimmune serum and streptomycin. Am J Med 1946, 1:180-188.
29. Drabick J.J., Narayanan R.B., Williams J.C., Leduc J.W., Nacy C.A. Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine. Am J Med Sci 1994, 308:83-87.
30. Fulop M., Mastroeni P., Green M., Titball R.W. Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine 2001, 19:4465-4472.
31. Rhinehart-Jones T.R., Fortier A.H., Elkins K.L. Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells. Infect Immun 1994, 62:3129-3137.
32. Klimpel G.R., Eaves-Pyles T., Moen S.T., Taormina J., Peterson J.W., Chopra A.K., et al. Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody. Vaccine 2008, 26:6874-6882.